PIRS Key Statistics, Chart & Performance
The current stock price of PIRS is 13.6 USD. In the past month the price decreased by -14.73%. In the past year, price increased by 2.97%.
PIRS Latest News, Press Relases and Analysis
PIRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.89 | 399.01B | ||
| AMGN | AMGEN INC | 15.55 | 183.12B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 154.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.92 | 109.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.39 | 77.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 906.05 | 61.05B | ||
| INSM | INSMED INC | N/A | 44.50B | ||
| NTRA | NATERA INC | N/A | 32.57B | ||
| BIIB | BIOGEN INC | 10.63 | 26.10B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 20.52B | ||
| INCY | INCYTE CORP | 15.88 | 20.02B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About PIRS
Company Profile
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Company Info
PIERIS PHARMACEUTICALS INC
225 Franklin Street, 26th Floor
Boston MASSACHUSETTS 02109 US
CEO: Stephen S. Yoder
Employees: 48
Phone: 18572468998
PIERIS PHARMACEUTICALS INC / PIRS FAQ
Can you describe the business of PIERIS PHARMACEUTICALS INC?
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
What is the current price of PIRS stock?
The current stock price of PIRS is 13.6 USD. The price decreased by -15.69% in the last trading session.
Does PIRS stock pay dividends?
PIRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of PIRS stock?
PIRS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of PIERIS PHARMACEUTICALS INC (PIRS) based on its PE ratio?
PIERIS PHARMACEUTICALS INC (PIRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.61).
Can you provide the market cap for PIERIS PHARMACEUTICALS INC?
PIERIS PHARMACEUTICALS INC (PIRS) has a market capitalization of 108.39M USD. This makes PIRS a Micro Cap stock.
Can you provide the ownership details for PIRS stock?
You can find the ownership structure of PIERIS PHARMACEUTICALS INC (PIRS) on the Ownership tab.
PIRS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PIRS. When comparing the yearly performance of all stocks, PIRS is a bad performer in the overall market: 72.72% of all stocks are doing better.
PIRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PIRS. PIRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PIRS Financial Highlights
Over the last trailing twelve months PIRS reported a non-GAAP Earnings per Share(EPS) of -12.61. The EPS increased by 54.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.74% | ||
| ROE | -98.06% | ||
| Debt/Equity | 0 |
PIRS Forecast & Estimates
For the next year, analysts expect an EPS growth of 42.86% and a revenue growth -79.28% for PIRS